Promising combo tackles rare immune storm in adults
NCT ID NCT07531069
First seen May 13, 2026 · Last updated May 21, 2026 · Updated 3 times
Summary
This study tested a combination of two drugs—interferon-gamma monoclonal antibody and dexamethasone—in 22 adults with a severe immune condition called refractory secondary HLH. The goal was to see if the treatment could help patients recover and how safe it was. Participants received the drugs as part of their care and were monitored with blood tests and checkups for 8 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HLH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huadong Hospital, Fudan University
Shanghai, Shanghai Municipality, 200040, China
Conditions
Explore the condition pages connected to this study.